FOLH1 and metastatic malignant neoplasm in the lymph nodes: analyzed recurrence patterns in 108 patients after 68Ga-prostate specific membrane antigen (PSMA) ligand PET/CT-guided RT (without additional systemic treatment) for recurrent oligometastatic disease, including in 45% pelvic and 18% extrapelvic lymph node metastases.